Orexo AB
STO:ORX
Orexo AB
Operating Income
Orexo AB
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orexo AB
STO:ORX
|
Operating Income
-kr140.3m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-19%
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Operating Income
-kr353.1m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Operating Income
kr477.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
E
|
Enzymatica AB (publ)
STO:ENZY
|
Operating Income
-kr52.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Operating Income
kr225m
|
CAGR 3-Years
52%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Operating Income
-kr106.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Orexo AB
Glance View
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
See Also
What is Orexo AB's Operating Income?
Operating Income
-140.3m
SEK
Based on the financial report for Dec 31, 2024, Orexo AB's Operating Income amounts to -140.3m SEK.
What is Orexo AB's Operating Income growth rate?
Operating Income CAGR 10Y
-19%
Over the last year, the Operating Income growth was -29%. The average annual Operating Income growth rates for Orexo AB have been 14% over the past three years , and -19% over the past ten years .
You don't have any saved screeners yet